Eli Lilly has climbed 37 positions over the past month to reach 76th in the Favored Green Zone of the SIA S&P 500 Index Report, alongside a Double Top signal. Yet its ranking remains 50 places lower over the quarter despite outperforming the benchmark; a contrast that adds context to the recent technical improvement.